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Abstract
AIM: Mechanisms underlying the chemopreventive effects
of cyclooxygenase (COX) inhibitors remain elusive. We have
previously shown that celecoxib but not indomethacin could
prevent carcinogen-induced gastric cancer development
in Wistar rats. This chemopreventive effect appeared to be
independent of COX-2 and prostaglandin (PG) E2 suppression
since the lowest PGE2 was obtained in indomethacin group.
This study compared the cell kinetic changes in stomachs
of rats after treatment with celecoxib (5, 10, 20 mg/(kg·d))
or indomethacin (3 mg/(kg·d)) to gain more insights into
the chemopreventive mechanism.
METHODS: The apoptosis and proliferation indexes in
gastric tumor, adjacent non-cancer tissues and normal
gastric tissues were determined. Apoptosis was quantified
by apoptotic nuclei counting and TUNEL, whereas proliferation
was determined by Ki67 immunostaining.
RESULTS: Treatment with either celecoxib or indomethacin
inhibited gastric tumor proliferation by more than 65%
(P<0.02). However, celecoxib caused a dose-dependent
increase in apoptosis (P<0.05) which was not seen in
indomethacin-treated tumors (P = 0.54). The highest
apoptosis to proliferation ratio was seen in tumors treated
with celecoxib at 10 mg/(kg·d). Treatment with this dose
of celecoxib was associated with the lowest incidence of
gastric cancer development.
CONCLUSION: Our findings suggest that the difference in
chemopreventive effects of indomethacin and celecoxib in
this animal model of gastric carcinogenesis is largely due
to the differential cell kinetic changes, which does not
correlate with the degree of COX-2 and PG suppression.
© 2005 The WJG Press and Elsevier Inc. All rights reserved.
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INTRODUCTION
Gastric cancer is the leading cause of cancer deaths in China.
Interestingly, treatment with non-steroidal anti-inflammatory
drugs (NSAIDs) including aspirin has been shown to reduce
the risk of gastric cancer development in epidemiological
studies[1-3]. However, the molecular mechanisms underlying the
chemopreventive effect of NSAIDs remain poorly understood.
There is accumulating evidence that NSAIDs exert their anti-
neoplastic effect by inhibition of COX and prostaglandin[4,5].
The COX enzyme has two isoforms. COX-1 is constitutively
expressed whereas COX-2 isoform is inducible. Notably,
overexpression of COX-2 is frequently detected in human gastric
cancer[6,7]. This expression is associated with uncontrolled cell
proliferation and differentiation, inhibition of apoptosis, increase
in angiogenesis, metastasis and evasion of immunological
surveillance[8,9]. Accordingly, suppression of COX-2 appears to
be the mechanism underlying the chemopreventive effect of
NSAIDs. Treatment with specific COX-2 inhibitors suppresses
the growth of gastric cancer xenografts in nude mice by inducing
apoptosis and suppressing replication of the neoplastic cells[10].
      However, recent reports suggest that the anti-neoplastic
effects of NSAIDs might be independent of COX inhibition[11-13].
It has been found that agents that do not inhibit COX-2, such
as sulindac sulfone, could also induce apoptosis in vitro and
inhibit colorectal carcinogenesis in animal models[14]. Moreover,
the use of low dose aspirin, which has virtually no COX-2
inhibitory effect, could reduce colorectal adenoma development
in high risk individuals[15].
       Recently, we have examined the chemopreventive effect of
specific COX-2 inhibitors (celecoxib) and non-selective
COX inhibitors (indomethacin) in a rat model of gastric
carcinogenesis[16]. We showed that treatment with celecoxib,
but not indomethacin, beginning shortly after carcinogen
administration inhibited the growth and development of gastric
tumors. Intriguingly, both COX-2 and prostaglandin E2 levels
were lower in indomethacin-treated group than in celecoxib
treated group, suggesting that the chemopreventive effect of
celecoxib may not be mediated by inhibition of COX-2 activity
or prostaglandin production alone. The present study was
designed to clarify the cell kinetic changes in stomachs of rats
after treatment with celecoxib or indomethacin in order to gain
more insights into the pathogenetic mechanism underlying the
chemopreventive effect of celecoxib.
MATERIALS AND METHODS
Experimental design
The details of animal experimentation were reported previously[16].
Briefly, 4 week-old grade 2 male Wistar rats (weighing around
60 g) were used. The rats were fed with food and water ad
libitum and maintained on hardwood bedding under a 12-h
light/dark cycle. Animals were weighed weekly during the
experiments.
     Primary gastric adenocarcinomas were induced by oral
administration of N-methyl-N’-nitro-N-nitrosoguanidine
(MNNG) as described previously[17,18]. MNNG (Fluko, Germany)
was prepared every other day with distilled water into a
concentration of 100 g/mL and was given to rats as drinking
water. In addition, 1 mL of 10% sodium chloride was given
weekly by oral gavage in the initial 6 wk to enhance gastric
cancer development[18]. All experiments were approved by the
Sun Yat-Sen University Animal Experimentation and Ethics
Committee.
     Rats were randomly allocated to 6 different treatment
groups as shown in Table 1: Group A: untreated control (n = 5),
group B: MNNG control (n = 16), group C: MNNG plus
celecoxib at 5 mg/(kg·d) (n = 17), group D: MNNG plus celecoxib
at 10 mg/(kg·d) (n = 16), group E: MNNG plus celecoxib at
20 mg/(kg·d) (n = 16) and group F: MNNG plus indomethacin
at 3 mg/(kg·d) (n = 16). The dosages of these drugs were
based on corresponding human doses and previous animal
chemopreventive studies[10,11]. All drug treatments were
commenced on d 7 after the introduction of MNNG and
continued for 40 wk. All animals were then sacrificed at the
end of study.
        Gastric tumor (T), adjacent non-tumor site (NT), macroscopically
normal gastric mucosa from non-tumor rats (N) in the same
treatment group were obtained. In untreated control rats, normal
gastric tissues were obtained as control (C). All gastric tissues
were fixed in 10% buffered formalin for histological processing.
Determination of apoptotic index
Apoptosis was determined by apoptotic nuclei counting.
Sections were stained with hematoxylin and eosin to evaluate
the number of apoptotic cells per section. The criteria used to
recognize apoptotic cells were: shrunk size, loss of contact
with surrounding tissues (at times forming the classically
described halo) and nuclear condensation as previously
described[19]. At least 1 000 cells were counted in five random
fields and the percentage of cells with apoptotic features was
then calculated (apoptotic index or AI). The apoptotic nuclei
counts were compared with findings obtained by terminal
deoxynucleotidy transferase (TdT)-mediated deoxyuridine
triphosphate nick-end labeling (TUNEL) technique (DeadEndTM
Colorimetric TUNEL System; Promega, Madison, WI, USA) in
30 randomly selected cases (Figures 1A, B). A strong correlation
between apoptotic nuclei count and TUNEL results was found
(r = 0.86, P<0.001).
Determination of proliferation index
Proliferation was assayed by immunoperoxidase staining for
Ki-67 as described previously[19]. Briefly, paraffin-embedded
sections from each specimen were labeled with anti-Ki-67
antibody (ab833; abcam, Cambridge, UK) after microwave
antigen retrieval in citrate buffer. Negative controls were
run by replacing the primary antibody with non-immune
serum. The slides were developed in 3,3-diaminobenzidine
tetrahydrochloride (DAB, Dako, Denmark) and counter-stained
with Mayer haematoxylin (Figure 1). The proliferation index
(PI) was expressed as a percentage of the ratio of Ki-67-positive
nuclei to the total nuclei counted.
Statistical analysis
Results were expressed as mean±SE. Comparisons among
different treatment groups were made by (analysis of variance)
ANOVA with Bonferroni’s multiple comparison tests. P<0.05
was considered statistically significant. All statistical calculations
were carried out using the SPSS statistical software package
(version 11.0, SPSS Inc.).
RESULTS
Chemopreventive effects of celecoxib
The percentage of rats that developed gastric cancer in each
treatment group is summarized in Table 1. Whilst none of the
control rats in group A developed gastric cancer, 75% of MNNG
treated rats (group B) had gastric cancer (P = 0.002, Table 1).
Treatment with celecoxib at 10 mg/(kg·d) (18.8%, P = 0.004) and
20 mg/(kg·d) (31.3%, P = 0.052) was associated with lower
incidences of gastric cancer development than MNNG control.
However, administration of celecoxib 5 mg/kg or indomethacin
3 mg/kg had no significant reduction in tumor incidence.
Table 1  Incidence of gastric tumors in different treatment
groups
Group Treatment           Total no.   No. of       Tumor
of rats   rats with    incidence
    tumor         (%)
A Control                                                5             0   0
B MNNG alone                                     16           12 75.01
C MNNG+celecoxib 5 mg/kg              17           12 70.6
D MNNG+celecoxib 10 mg/kg            16             3 18.8
E MNNG+celecoxib 20 mg/kg            16             5 31.3
F MNNG+indomethacin 3 mg/kg      16           11 68.8
1P = 0.002 (ANOVA) (groups B vs D, P = 0.004, groups B vs E,
P = 0.052).
Effect of celecoxib or indomethacin on gastric epithelial cell
apoptosis
The mean apoptotic indexes in gastr ic tumors, their
corresponding adjacent normal tissues and non-tumor gastric
tissues of different treatment groups are shown in Figure 2A.
The apoptotic index was generally higher in gastric tumors
than in their adjacent non-tumor and normal gastric tissues
(P<0.005, ANOVA). Specifically, there was a significant
difference in the apoptotic indexes among tumor, adjacent
non-cancer tissues and normal gastric tissues in group B as
MNNG control (P = 0.001), groups C to E treated with celecoxib
(P<0.005) and group F treated with indomethacin (P = 0.003).
       Whilst the mean apoptotic index was 0.50% in MNNG treated
tumors, there appeared to be a dose-dependent increase in
the apoptotic index of gastric tumors treated with celecoxib
(P<0.05, ANOVA). The corresponding mean tumor apoptotic
indexes in rats treated with celecoxib 5 mg/(kg·d), celecoxib
10 mg/(kg·d) and celecoxib 20 mg/(kg·d) were 0.78% (P = 0.015
vs group B), 1.02% (P = 0.041 vs group B) and 1.12% (P = 0.093
vs group B), respectively. In contrast, indomethacin failed to
induce apoptosis in gastric tumor (0.57% vs 0.50%, P = 0.54).
Moreover, there was a significant difference in apoptotic indexes
in the adjacent non-tumor tissues among different treatment
groups (P = 0.003, ANOVA). The apoptotic index in non-tumor
tissues increased from 0.13% in group B MNNG to 0.43% in
celecoxib 5 mg/(kg·d) (P = 0.009), 0.56% in celecoxib 10 mg/(kg·d)
(P = 0.01), 0.48% in celecoxib 20 mg/(kg·d) groups (P<0.001)
and 0.42% in indomethacin group (P<0.05), respectively. On
the other hand, the apoptotic index in the normal stomachs of
non-tumor rats was low and comparable among different
treatment groups (P = 0.39).
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Effect of celecoxib or indomethacin on gastric epithelial cell
proliferation
The highest proliferation index (22.1%) was seen in gastric
tumors of MNNG-treated rats. Treatment with either celecoxib
or indomethacin significantly reduced the tumor proliferation
index (P<0.001, ANOVA; Figure 2B). The corresponding
proliferation index in tumors treated with celecoxib 5, 10 and
20 mg/(kg·d) was 7.6% (P<0.001 vs group B), 2.9% (P = 0.012 vs
group B) and 4.6% (P<0.001 vs group B) respectively. Celecoxib
at 5, 10 and 20 mg/(kg·d) inhibited tumor proliferation by 65.6%,
Figure 1  Histological examination of apoptosis and proliferation. Apoptosis was examined by apoptotic nuclei counting (A) and verified
by TUNEL (B). A representative apoptotic nucleus is illustrated by the black arrow. Representative H&E stained sections showing
apoptotic bodies (red arrow) in (C) MNNG-treated tumors, (D) celecoxib-treated tumors and (E) indomethacin-treated tumors. (F-H)
Ki-67 immunostaining was used in the assessment of proliferation. Representative proliferating cells in (F) MNNG treated tumors, (G)
celecoxib-treated tumors and (H) indomethacin-treated tumors indicated by positive immunoreactivity against Ki-67.
Figure 2  Effects of celecoxib/indomethacin treatment on gastric cell apoptosis and proliferation. A: Effects of celecoxib/
indomethacin treatment on gastric cell apoptosis. The mean apoptotic index with standard error was shown. The apoptotic
indexes were significantly higher in MNNG-induced tumor than in untreated control (P = 0.001). Moreover, the levels of
apoptosis were significantly different among tumors (T), their adjacent non-tumor tissues (NT) and normal tissues from non-
tumor rats (N) in all treatment groups (aP<0.005, ANOVA). Treatment with celecoxib was associated with a higher apoptotic
index in tumors (P<0.05, ANOVA) and their adjacent non-tumor tissues (P = 0.003, ANOVA). There appeared to be a dose-
dependent increase in apoptotic index in celecoxib-treated tumors when compared to tumors treated with MNNG alone, but
there was no significant increase in apoptotic index in indomethacin-treated tumors; B: The mean proliferation indexes with
standard error. There were significant differences in the proliferation indexes among tumors (P≤0.001, ANOVA) and their
adjacent normal gastric tissues (P = 0.01, ANOVA). Specifically, tumors in MNNG group had the highest proliferation index than
other treatment groups (group B vs all other groups, P<0.003).
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86.9% and 79.2% respectively. Notably, the maximal anti-
proliferative effect was achieved with celecoxib treatment at
10 mg/(kg·d). In contrast to apoptosis, similar anti-proliferative
effects were noted in indomethacin-treated tumors (68.8%
reduction, P<0.001 vs group B).
     In adjacent normal tissues, there was also a significant
difference in the proliferation indexes among different treatment
groups (P = 0.01, ANOVA). The highest proliferation index was
found in the adjacent non-tumor tissues of group B MNNG
treated rats (16.1%). The corresponding proliferation indexes
in non-tumor tissues of rats treated with celecoxib 5 mg/(kg·d),
10 mg/(kg·d) and 20 mg/(kg·d) were 2.44% (or 85% reduction,
P = 0.012 vs group B), 5.21% (or 67.6% reduction, P>0.05 vs
group B) and 3.63% (77.5% reduction, P>0.05 vs group B). In
contrast, there was no significant suppression of proliferation
in non-tumor tissues of indomethacin group (10.7%, P>0.05 vs
group B). It was interesting to note that the proliferation of
non-tumor gastric tissues appeared to be higher in indomethacin
group than in those treated with celecoxib or MNNG control.
Effects of celecoxib or indomethacin on ratio of apoptotic to
proliferation index
We also analyzed the ratio of apoptotic index to proliferation
index (AI/PI) in gastric tumors of different treatment groups.
As shown in Figure 3, there was a significant difference in the
ratio among different treatment groups (P = 0.026, ANOVA). As
shown in Table1, the AI/PI ratio was found to be inversely
proportional to the tumor incidences of different treatment
groups. The lowest AI/PI ratio (0.03±0.012) was seen in group
B MNNG-treated tumors which had the highest tumor incidence
(75%). In contrast, the highest AI/PI ratio (0.51±0.34) was seen
in rats treated with celecoxib at 10 mg/(kg·d) (Group D) with the
lowest tumor incidence (18.8%).
Figure 3  Effects of celecoxib or indomethacin on the apoptosis
index to proliferation ratio (AI/PI) of gastric tumors. The mean
AI/PI ratio with standard error was shown. There was a sig-
nificant difference in the AI/PI ratio among different treatment
groups (P = 0.026, ANOVA). The highest ratio was seen in
gastric tumors treated with celecoxib at 10 mg/(kg·d) whereas
the lowest ratio was seen in tumors from MNNG group. The
AI/PI ratio appeared to inversely correlate with the tumor
incidence reported in different treatment groups (Table 1).
DISCUSSION
We have demonstrated in our recent study[16] that treatment
with celecoxib, but not indomethacin could significantly reduce
the number of gastric tumor formations in rats and the maximal
chemopreventive effect was seen in rats treated with a moderate
dose of celecoxib 10 mg/(kg·d). Intriguingly, the lowest COX-2
and PGE2 levels were detected in indomethacin-treated tumors
but not in celecoxib-treated groups, suggesting that the
chemopreventive effect may not be mediated by COX-2 or PGE2
suppression alone. This study aimed to characterize the cell kinetic
changes in stomachs of rats after treatment with celecoxib or
indomethacin in order to gain more insights into the mechanisms
underlying the chemopreventive effects of celecoxib. We found
that treatment with celecoxib at all doses 5-20 mg/(kg·d) or
indomethacin caused a marked inhibition of proliferation in
gastric tumors and their adjacent normal tissues. On the other
hand, it was noted that induction of apoptosis was only noticed
in celecoxib-treated tumors but not in indomethacin-treated
tumors. Together, celecoxib treatment resulted in both induction
of apoptosis and inhibition of proliferation. In contrast,
indomethacin was found to inhibit cell proliferation without
induction of apoptosis in gastric tumors. These findings
suggest that the mechanisms underlying the chemopreventive
effect of celecoxib may be more related to its ability to induce
apoptosis which was not found in indomethacin-treated
group. More importantly, these findings help to explain the
divergent chemopreventive responses of rat stomachs to these
two agents which could not be explained by the level of COX-2
inhibition alone.
      Although there was no induction of apoptosis by indomethacin
in gastric tumors, we noticed that both indomethacin and
celecoxib induced apoptosis in adjacent normal gastric tissues.
The reason for this discrepant finding remains elusive but it is
possible that neoplastic transformation of gastric epithelial cells
may render them less susceptible to the pro-apoptoic effects of
indomethacin. Intuitively, the use of a higher dose of indomethacin
might be able to induce apoptosis in gastric tumor cells. The
use of this dosage of 3 mg/(kg·d) is supported by previous animal
chemopreventive studies[10,11] and human daily recommendations.
Moreover, results from our previous study[16] provide unequivocal
evidence that the current dosage is adequate in suppressing
COX-2 and PGE2. Future studies may be necessary to characterize
the effects of a high dose of indomethacin in gastric cancer
chemoprevention. However, the use of a higher dosage may
result in more gastrointestinal toxicity as reflected by the
heightened proliferation in non-tumor tissues treated with the
current dose of indomethacin (Figure 2B). This increase in
gastric proliferation may be a compensatory response to the
topical erosive effect of non-selective NSAIDs.
      Moreover, the current study helps to explain the optimal
dose of celecoxib used in chemoprevention of gastric cancer.
As shown in Figure 3, treatment with celecoxib at 10 mg/(kg·d)
was associated with the highest AI/PI ratio. Although we have
shown in our previous study[16] that the high dose celecoxib
20 mg/(kg·d) is associated with greater suppression of COX-2
activity and PGE2 level, this is not associated with a parallel rise
in AI/PI ratio and higher chemopreventive effects. In line with
our findings, Nishimura et al[20] reported that induction of
apoptosis was noted after treatment with a COX-2 inhibitor at a
lower concentration than for the suppression of cell proliferation
in a cancer xenograft model. It thus appears that the optimal
dosage of celecoxib in chemoprevention is the dosage with the
highest apoptosis to proliferation ratio.
      Apart from suppression of prostaglandins, other possible
pathways by which COX-2 inhibitors exert their pro-apoptotic
effects have been previously addressed. It has been shown
that NS398, a specific COX-2 inhibitor, could induce apoptosis
in COX-2 expressing esophageal cancer cell line through the
cytochrome C-dependent pathway with activation of Caspase-9
and Caspase-3[21]. This is associated with minimal alterations
in bcl-2, bax, c-myc, Fas and Fas-ligand expressions. A recent
study also showed that celecoxib could induce apoptosis via a
novel apoptosome-dependent but Bcl-2-independent
mitochondrial pathway[22]. Both Fas-associated death domain
protein and Bcl-2 are not involved in the induction of apoptosis
by celecoxib in Jurkat T cells. This effect also appears to be
independent of the ability to block COX-2. In addition, the
failure of indomethacin to inhibit the development of MNNG-
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induced gastric cancer may be explained by the inability of
indomethacin to inhibit the activity of IB kinase [23]. The NF-B
signaling pathway is another potential non-COX mediated-
carcinogenesis pathway[24]. Activated NF-B could translocate
into the nuclei where it modulates the expression of a variety
of genes, mostly through IB kinase (IKK)-dependent
phosphorylation and subsequent degradation of its inhibitors.
It has been recognized that aspirin and sulindac, but not
indomethacin, can inhibit the activity of IB kinase  in vitro.
Therefore, the failure of indomethacin to inhibit IB kinase 
may result in less COX-independent tumor suppression.
Whether the difference in IB kinase  inhibitory effects
accounts for the differences in outcomes between indomethacin
and celecoxib warrants further investigation.
     In conclusion, these data help to explain the divergent
chemopreventive effects of celecoxib and indomthacin in this
animal model of gastric carcinogenesis. The chemopreventive
effect of celecoxib is largely mediated by induction of apoptosis
through a probable COX2-independent pathway. Further
studies are necessary to characterize the pathways involved
and the possible role of celecoxib in chemoprevention of human
gastric cancer.
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